Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2010

01-12-2010 | Research Article

The incidence of potential drug–drug interactions in elderly patients with arterial hypertension

Authors: Vesna Bacic-Vrca, Srecko Marusic, Viktorija Erdeljic, Slaven Falamic, Nives Gojo-Tomic, Dario Rahelic

Published in: International Journal of Clinical Pharmacy | Issue 6/2010

Login to get access

Abstract

Objective To assess the incidence and type of potential, clinically significant drug–drug interactions in elderly outpatients with arterial hypertension. Setting Three community pharmacies in Croatia. Method Eligible patients were aged 65 or older, treated for arterial hypertension and received 2 or more drugs. Potential interactions were identified by Lexi-Interact software. The software categorized each potential interaction according to clinical significance in five groups: (A) No known interaction; (B) Specified agents may interact, but there is little to no evidence of clinical concern; (C) Specified agents may interact in a clinically significant manner. Monitoring therapy is suggested; (D) The two medications may interact in a clinically significant manner. Modification of therapy is suggested; (X) Contraindicated combination. Interactions of level C, D and X were considered clinically significant. Main outcome measure The incidence and type of potential drug–drug interactions. Results There were 265 patients included in the study. Potential, clinically significant drug interactions were identified in 240 (90.6%) patients, out of which 97.9% had interactions with clinical significance C, 20.4% D, and 0.8% X. The median number of drug interactions per patient was 4. We identified 215 drug combinations with the potential to cause clinically significant interaction, out of which 83.3% had clinical significance C, 16.3% clinical significance D, and 0.4% clinical significance X. Conclusion Drug–drug interactions are common in elderly hypertensive patients. Computer-based screening could help pharmacists and physicians to recognize potential, clinically significant interactions.
Literature
1.
go back to reference Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, et al. Drug–drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc. 1996;44:944–8.PubMed Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, et al. Drug–drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc. 1996;44:944–8.PubMed
2.
go back to reference Becker ML, Visser LE, van Gelder T, Hofman A, Stricker BH. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years. Drugs Aging. 2008;25(2):145–52.CrossRefPubMed Becker ML, Visser LE, van Gelder T, Hofman A, Stricker BH. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or = 55 years. Drugs Aging. 2008;25(2):145–52.CrossRefPubMed
3.
go back to reference Stafford AC, Tenni PC, Peterson GM, Jackson SL, Hejlesen A, Villesen C, et al. Drug-related problems identified in medication reviews by Australian pharmacists. Pharm World Sci. 2009;31(2):216–23.CrossRefPubMed Stafford AC, Tenni PC, Peterson GM, Jackson SL, Hejlesen A, Villesen C, et al. Drug-related problems identified in medication reviews by Australian pharmacists. Pharm World Sci. 2009;31(2):216–23.CrossRefPubMed
4.
go back to reference Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.CrossRefPubMed Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.CrossRefPubMed
5.
go back to reference ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14(5):488–98.CrossRefPubMed ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14(5):488–98.CrossRefPubMed
6.
go back to reference Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.CrossRefPubMed Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.CrossRefPubMed
7.
go back to reference Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000;38(11):504–13.PubMed Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther. 2000;38(11):504–13.PubMed
8.
go back to reference Goldberg RM, Mabee J, Chan L, Wong S. Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.CrossRefPubMed Goldberg RM, Mabee J, Chan L, Wong S. Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.CrossRefPubMed
11.
go back to reference Erceg M, Hrabak-Zerjavić V, Ivicević Uhernik A. Regional characteristics of arterial hypertension in adult population of Croatia. Acta Med Croatica. 2007;61(3):293–8.PubMed Erceg M, Hrabak-Zerjavić V, Ivicević Uhernik A. Regional characteristics of arterial hypertension in adult population of Croatia. Acta Med Croatica. 2007;61(3):293–8.PubMed
12.
go back to reference Prisant LM. Now or never: optimal antihypertensive therapy in the elderly. Prev Cardiol. 2008;11(4):201–9.CrossRefPubMed Prisant LM. Now or never: optimal antihypertensive therapy in the elderly. Prev Cardiol. 2008;11(4):201–9.CrossRefPubMed
13.
go back to reference Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf. 2006;29(1):79–90.CrossRefPubMed Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf. 2006;29(1):79–90.CrossRefPubMed
14.
go back to reference Mannheimer B, Ulfvarson J, Eklöf S, Bergqvist M, von Bahr C. A clinical evaluation of the Janus Web Application, a software screening tool for drug-drug interactions. Eur J Clin Pharmacol. 2008;64:1209–14.CrossRefPubMed Mannheimer B, Ulfvarson J, Eklöf S, Bergqvist M, von Bahr C. A clinical evaluation of the Janus Web Application, a software screening tool for drug-drug interactions. Eur J Clin Pharmacol. 2008;64:1209–14.CrossRefPubMed
16.
go back to reference Carter BL, Lund BC, Hayase N, Chrischilles E. The extent of potential antihypertensive drug interactions in a Medicaid population. Am J Hypertens. 2002;15(11):953–7.CrossRefPubMed Carter BL, Lund BC, Hayase N, Chrischilles E. The extent of potential antihypertensive drug interactions in a Medicaid population. Am J Hypertens. 2002;15(11):953–7.CrossRefPubMed
17.
go back to reference Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38:666–71.CrossRefPubMed Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38:666–71.CrossRefPubMed
18.
go back to reference Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61:675–81.CrossRefPubMed Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61:675–81.CrossRefPubMed
19.
go back to reference Mackenzie IS, MacDonald TM. Treatment of osteoarthritis in hypertensive patients. Expert Opin Pharmacother. 2010;11(3):393–403.CrossRefPubMed Mackenzie IS, MacDonald TM. Treatment of osteoarthritis in hypertensive patients. Expert Opin Pharmacother. 2010;11(3):393–403.CrossRefPubMed
20.
go back to reference Gyamlani G, Geraci SA. Secondary hypertension due to drugs and toxins. South Med J. 2007;100(7):692–9.PubMed Gyamlani G, Geraci SA. Secondary hypertension due to drugs and toxins. South Med J. 2007;100(7):692–9.PubMed
21.
go back to reference Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641–51.CrossRefPubMed Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641–51.CrossRefPubMed
22.
go back to reference Yoon SL, Schaffer SD. Herbal, prescribed, and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs. 2006;27(2):118–29.CrossRefPubMed Yoon SL, Schaffer SD. Herbal, prescribed, and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs. 2006;27(2):118–29.CrossRefPubMed
23.
go back to reference Pavlicević I, Kuzmanić M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15(3):E372–82.PubMed Pavlicević I, Kuzmanić M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15(3):E372–82.PubMed
24.
go back to reference Benson M, Marangou A, Russo MA, Durocher J, Collaku A, Starkey YY. Patient preference for sustained-release versus standard paracetamol (acetaminophen): a multicentre, randomized, open-label, two-way crossover study in subjects with knee osteoarthritis. J Int Med Res. 2009;37(5):1321–35.PubMed Benson M, Marangou A, Russo MA, Durocher J, Collaku A, Starkey YY. Patient preference for sustained-release versus standard paracetamol (acetaminophen): a multicentre, randomized, open-label, two-way crossover study in subjects with knee osteoarthritis. J Int Med Res. 2009;37(5):1321–35.PubMed
26.
go back to reference Radosević N, Gantumur M, Vlahović-Palcevski V. Potentially inappropriate prescribing to hospitalised patients. Pharmacoepidemiol Drug Saf. 2008;17(7):733–7.CrossRefPubMed Radosević N, Gantumur M, Vlahović-Palcevski V. Potentially inappropriate prescribing to hospitalised patients. Pharmacoepidemiol Drug Saf. 2008;17(7):733–7.CrossRefPubMed
27.
go back to reference Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28(7):601–31.CrossRefPubMed Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28(7):601–31.CrossRefPubMed
28.
go back to reference Mogensen CE. New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. J Hum Hypertens. 2005;19(Suppl 1):S15–20.CrossRefPubMed Mogensen CE. New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. J Hum Hypertens. 2005;19(Suppl 1):S15–20.CrossRefPubMed
29.
go back to reference Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48(2):133–43.CrossRefPubMed Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48(2):133–43.CrossRefPubMed
30.
go back to reference Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther. 2008;84(3):403–11.CrossRefPubMed Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther. 2008;84(3):403–11.CrossRefPubMed
31.
go back to reference Johnell K, Fastbom J. The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry. 2009;24(7):731–8.CrossRefPubMed Johnell K, Fastbom J. The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry. 2009;24(7):731–8.CrossRefPubMed
32.
go back to reference Assem-Hilger E, Jungwirth S, Weissgram S, Kirchmeyr W, Fischer P, Barnas C. Benzodiazepine use in the elderly: an indicator for inappropriately treated geriatric depression? Int J Geriatr Psychiatry. 2009;24(6):563–9.CrossRefPubMed Assem-Hilger E, Jungwirth S, Weissgram S, Kirchmeyr W, Fischer P, Barnas C. Benzodiazepine use in the elderly: an indicator for inappropriately treated geriatric depression? Int J Geriatr Psychiatry. 2009;24(6):563–9.CrossRefPubMed
33.
go back to reference Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380–5.PubMed Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380–5.PubMed
Metadata
Title
The incidence of potential drug–drug interactions in elderly patients with arterial hypertension
Authors
Vesna Bacic-Vrca
Srecko Marusic
Viktorija Erdeljic
Slaven Falamic
Nives Gojo-Tomic
Dario Rahelic
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9442-5

Other articles of this Issue 6/2010

International Journal of Clinical Pharmacy 6/2010 Go to the issue